Glucagon-like peptide 1 receptor: Difference between revisions
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
== Relevance == | == Relevance == | ||
GLP-1R agonists are used in treatment of type 2 diabetes<ref>PMID:21950636</ref>. GLP-1 analogues can cross the brain-blood barrier and stimulate the GLP-1R in the brain. This stimulation is affecting mitochondrial functioning, protein aggregation, neuroinflammation, synaptic plasticity, learning and memory in models of Parkinson Disease and Alzheimer Disease<ref>PMID:26851597</ref>. | GLP-1R agonists are used in treatment of type 2 diabetes<ref>PMID:21950636</ref>. GLP-1 analogues can cross the brain-blood barrier and stimulate the GLP-1R in the brain. This stimulation is affecting mitochondrial functioning, protein aggregation, neuroinflammation, synaptic plasticity, learning and memory in models of Parkinson Disease and Alzheimer Disease<ref>PMID:26851597</ref>. It is a member of the glucagon receptor family of [[G protein-coupled receptors]]. | ||
== Structural highlights == | == Structural highlights == | ||